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Edited by Horst FeldmannAbstract Angiogenesis is the process by which new blood vessels
are formed from existing vessels. The vascular endothelial growth
factors (VEGFs) are considered as key molecules in the process
of angiogenesis. The VEGF family currently includes VEGF-A,
-B, -C, -D, -E, -F and placenta growth factor (PlGF), that bind
in a distinct pattern to three structurally related receptor tyrosine
kinases, denoted VEGF receptor-1, -2, and -3. VEGF-C and
VEGF-D also play a crucial role in the process of lymphangio-
genesis. Here, we review the biology of VEGFs and evaluate their
role in pathological angiogenesis and lymphangiogenesis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Vascular endothelial growth factor (VEGF) is a speciﬁc
mitogen for vascular endothelial cells (EC). VEGF family con-
sists of seven members – VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, VEGF-F and placental growth factor
(PlGF). They share a common structure of eight characteristi-
cally spaced cysteine residues in a VEGF homology domain.
These members have diﬀerent physical and biological proper-
ties and act through speciﬁc tyrosine kinase receptors –
VEGFR-1, VEGFR-2 and VEGFR-3. Neuropilin-1 (Nrp-1)
and Nrp-2 are receptors for semaphorins, but they also bind
to some members of the VEGF family. VEGF/VEGF-receptor
system is a key component in the complex process of angiogen-
esis that also includes many other stimulators, inhibitors and
angiogenic modulators. VEGFR-3 and its ligands VEGF-C
and VEGF-D are important regulators of lymphangiogenesis,
while PlGF has been associated with arteriogenesis. VEGFs
are crucial in embryonic development and in other physiolog-
ical and pathological conditions, including wound healing,
rheumatoid arthritis, ocular neovascularization, tumor pro-
gression, endometriosis and cardiovascular diseases.2. VEGF-A
VEGF-A is a key molecule in induction of angiogenesis and
vasculogenesis it causes proliferation, sprouting, migration*Corresponding author. Fax: +358 17 163751.
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doi:10.1016/j.febslet.2006.03.087and tube formation of ECs [1]. VEGF-A gene is located at
chromosome 6p21.3 and is encoded by 8 exons separated by
7 introns. VEGF induces angiogenesis in a variety of physio-
logical and pathological conditions including embryogenesis,
corpus luteum formation, tumor growth, wound healing, and
compensatory angiogenesis in the heart.
VEGF-A mediates its responses primarily by activating
VEGFR-1 and VEGFR-2 but it also binds to Nrp-1 and
Nrp-2 [2]. Overexpression of VEGF-A produces a pronounced
strong angiogenic response in diﬀerent tissues. However result-
ing vessels are often large, dilated and leaky [3–5].
VEGF-A was initially described as a vascular permeability
factor secreted by carcinoma cell lines that enhanced perme-
ability in skin blood vessels and also stimulated the produc-
tion of ascites [6]. Molecular mechanisms by which VEGF-A
induces these eﬀects are not well characterized. It has been
postulated that VEGF-A increases permeability by binding
to VEGFR-2 and thereafter activating guanylyl cyclase and
cGMP via a nitric oxide dependent pathway. Increased
cGMP levels probably enhance endothelial permeability by
increasing the vesico-vascular organelles, fenestrations and
transcellular gaps [7]. VEGF-A mediated extravasation of
ﬂuid and plasma proteins, including ﬁbrin might contribute
to enhanced migration of ECs in extracellular matrix [8].
VEGF-A also causes vasodilatation by induction of endothe-
lial nitric oxide synthase (eNOS) and increasing nitric oxide
production [9].
VEGF-A promotes EC survival by inducing the expression
of anti-apoptotic proteins Bcl-2 and A1 in the ECs. This action
of VEGF-A might be related to the activation of phosphatidyl-
inositol-3 kinase and Bcl-2 pathways [10]. Most of the studies
on VEGF-A have primarily focused on their action on ECs.
However, the actions of VEGF-A on other cell types have also
been described. VEGF-A is mitogenic for retinal pigment epi-
thelial cells and Schwann cells. VEGF-A also has a neuropro-
tective eﬀect on hypoxic motor neurons, and is a modiﬁer of
amyotrophic lateral sclerosis [11]. Role of VEGF-A in vascular
smooth muscle cell proliferation and migration has also been
reported [12]. VEGF-A is also reported to have hematopoietic
eﬀects. It induces colony formation by mature subsets of gran-
ulocyte-macrophage progenitor cells and regulates hematopoi-
etic stem cell survival by an internal autocrine loop mechanism
[13] and promotes monocyte chemotaxis [14]. It also exerts
procoagulant activity via its ability to stimulate the production
of the potent initiator of coagulation tissue factor in ECs and
monocytes [14].blished by Elsevier B.V. All rights reserved.
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diﬀerent sizes (121, 145, 165, 183, 189 and 206 amino acid res-
idues) are known to exist. These isoforms have distinct but
overlapping functions in angiogenesis due to their diﬀerential
binding to heparan sulphate and neuropilins [1,15]. Through
alternative mRNA splicing, the VEGF-A isoforms diﬀer by
the presence or absence of sequences encoded by exons 6 and
7. VEGF-A121 does not bind to heparin or extracellular matrix
while VEGF-A165 has moderate heparin binding ability.
VEGF-A145 also contains a heparin binding domain and ele-
ments that enable the binding of VEGF-A145 to the extracellu-
lar matrix. VEGF-A189 and VEGF-A206 bind heparin more
strongly and are sequestered in the extracellular matrix and
at the cell surface and these two isoforms are probably less ac-
tive than either VEGF-A121 or VEGF-A165 in vivo. The three
secreted VEGF-A splice forms are VEGF-A121, VEGF-A145,
and VEGF-A165 while the VEGF-A183, VEGF-A189 and
VEGF-A206 are the matrix bound forms. Most VEGF-pro-
ducing cells express VEGF-A121, VEGF-A165, VEGF-A183
and VEGF-A189, but VEGF-A 145 and VEGF-A206 seem
to be restricted to cells of placental origin [1,15].
Homozygous VEGF-A knockout mice die at E8–E9 and
mice lacking even a single VEGF-A allele die at E11–E12 indi-
cating that VEGF-A expression at appropriate level is essential
during embryogenesis. Knockout studies in mice have also
suggested that the VEGF165 is probably the major isoform
that brings about the VEGF-A actions [1,15].
VEGF-A mRNA expression is induced by hypoxia. It is now
recognized that hypoxia-inducible factor-1a [HIF-1a] is a key
mediator of the hypoxic responses. In response to hypoxia,
HIF-1a binds to speciﬁc enhancer elements, resulting in
increased gene transcription. Hypoxia induces binding of
HIF-1a to the Hypoxia responsive element (HRE) in the
VEGF-A gene promoter region, which in turn increases
VEGF-A transcription. A role of von Hippel–Lindau (VHL)
tumor suppressor gene in HIF-1a dependent hypoxic re-
sponses has also been described [15,16]. Mutations in the
VHL gene are associated with increased angiogenesis, and
tumors with VHL mutation display increased VEGF-A expres-
sion. While hypoxia is important for VEGF-A regulation,
other pathways including growth factors, inﬂammatory
cytokines and hormones also up-regulate VEGF-A mRNA
expression [17].Fig. 1. Adenovirus mediated gene transfer of: (A) VEGF-A; (B) VEGF-D;
(D) PlGF to periadventital tissue resulted in formation of large tortuous bl
blocks the PlGF mediated angiogenesis; (F) sVEGFR-2 gene transfer with Pl
suggesting a role of VEGFR-1 and VEGFR-2 in PlGF mediated angiogene3. PlGF
Placental growth factor (PIGF) is a member of the VEGF
family which was ﬁrst identiﬁed in placenta but is also known
to be present in heart and lungs. Human PlGF gene has been
mapped to chromosome 14q24. PlGF-coding sequence is en-
coded by seven exons spanning an 800-kb-long DNA interval.
Four isoforms – PlGF-1, PlGF-2, PlGF-3 and PlGF-4, have
been described [18]. PlGF-1 and PlGF-3 are non-heparin
binding diﬀusible isoforms PlGF-2 and PlGF-4 have heparin
binding domains. PlGFs mediate their eﬀects through
VEGFR-1 [19]. PlGF-2 is also able to bind Nrp-1 and NrP-2
due to the insertion of 21 basic amino acids at the carboxy
terminus, while both PlGF-1 and PlGF-3 lack this amino acid
insert.
Results available from in vitro studies on the angiogenic role
of PlGF are inconsistent. In some studies PlGF binding to
VEGFR-1 failed to produce EC growth and angiogenesis
[20], while other studies show that PIGF/VEGFR-1 signaling
promotes EC viability and angiogenesis [20]. In placenta and
in PlGF-1 expressing tumors increased PlGF levels inhibit
EC growth [21]. PlGF has direct eﬀects on ECs, both by induc-
ing its own signaling and by amplifying VEGF-driven angio-
genesis [22]. PlGF-2 overexpression results in the production
of signiﬁcant angiogenesis in diﬀerent tissues [21,23]. Various
mechanisms by which PlGFs can enhance angiogenesis include
(a) intracellular signal transduction through VEGFRs; (b)
Increasing the fraction of VEGF-A available to activate
VEGFR-2 by displacing VEGF-A from the ‘VEGFR-1 sink’,
[22]; (c) Activation of VEGFR-1 by PlGFs results in intermo-
lecular transphosphorylation of VEGFR-2 that could increase
VEGF-A mediated angiogenesis [22]; (d) PlGF/VEGF-A het-
erodimer formation, which could act through VEGFR-1/
VEGFR-2 [22]. Our recent results show that PlGF-2 overex-
pression in perivascular tissue increased VEGF-A165 and
VEGF-A121 levels and produces signiﬁcant angiogenesis
(Fig. 1). These blood vessels were tortuous and well perfused.
PlGF-2 mediated angiogenesis was eﬀectively blocked by solu-
ble VEGFR-1 and VEGFR-2 receptors. This data suggests
that angiogenic responses to PlGF-2 are also indirectly medi-
ated through VEGFR-2 [20]. The proposed role of PlGF in
the process of arteriogenesis [24] is signiﬁcant and holds prom-
ise for the treatment of ischemic diseases.(C) VEGF-DDNDC (proteolytically processed form of VEGF-D); and
ood vessels in the adventitia; (E) sVEGFR-1 gene transfer with PlGF
GF also signiﬁcantly reduces the PlGF mediated angiogenesis, thereby
sis.
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increased macrophage accumulation occurs after injection of
PlGF protein [24] and adenovirus mediated PlGF gene transfer
[20]. Increased inﬁltration of macrophages presumably con-
tributes to the VEGF-A upregulation in the PlGF-2 trans-
duced arteries [21].
PlGF expression is upregulated during a number of patho-
logical conditions including non-small cell lung carcinoma
(NSCLC), colorectal cancer and wound healing, while, PlGF
levels are decreased in preeclampsia. A possible role of PlGF
in atherosclerosis has also been described [25].4. VEGF-B
The human VEGF-B gene spans about 4000 bp, contains
eight exons and six introns, and is located on chromosome
11, band q13. The promoter region of VEGF-B is diﬀerent
to that of VEGF-A, and this might explain diﬀerences in reg-
ulation by physiological stimuli. While both promoters are
associated with a CpG island and contain transcription factor
binding sites for Sp1 and AP-2, the VEGF-B promoter con-
tains Egr-1 sites, but lacks hypoxia-inducible factor-1 and
AP-1 sites found in the VEGF-A promoter. Consequently,
stimuli such as hypoxia which can induce VEGF-A expression
do not appear to regulate levels of VEGF-B [26].
VEGF-B167 and VEGF-B186 are the two isoforms that are
expressed in humans. The VEGF-B167 isoform is mainly ex-
pressed in the most tissues including skeletal muscles, myocar-
dium and brown fat and accounts for more than 80% of the
total VEGF-B transcripts. The VEGF-B186 isoform is ex-
pressed at lower levels and only in a limited number of tissues.
VEGF-B is a ligand for VEGFR-1 and Nrp-1, and it can form
heterodimers with VEGF-A [15,27]. Neither isoform binds
VEGFR-2 or VEGFR-3. VEGF-B167 binds heparan sulfate
proteoglycans and is mostly sequestered in the extracellular
matrix while VEGF-B186 is freely diﬀusible.
The precise role of VEGF-B in vivo is not precisely known.
Study with mice deﬁcient in VEGF-B reported development of
smaller hearts and impaired recovery after induced myocardial
infarction suggesting that formation of coronary collaterals
might be partly attributed to VEGF-B [28]. Also, VEGF-B
has been reported to be weakly angiogenic after adenoviral
delivery to periadventitial tissue or hindlimb skeletal muscle
[3,4]. Reduced synovial angiogenesis in VEGF-B knockout
arthritis models suggest a role of VEGF-B in inﬂammatory
angiogenesis [29].5. VEGF-C
The VEGF-C gene is located on chromosome 4q34. VEGF-
C genes comprise over 40 kb pairs of genomic DNA and
consist of seven exons. VEGF-C is produced as a precursor
protein and is proteolytically activated in the extracellular
space by proteases to generate a homodimeric protein with
high aﬃnity for both VEGFR- 2 and VEGFR-3. VEGF-C in-
duces mitogenesis, migration and survival of ECs. VEGF-C is
expressed in the heart, small intestine, placenta, ovary and the
thyroid gland in adults. Developmental studies, knockout
models and gene transfer experiments suggest that VEGF-C
is primarily a lymphangiogenic growth factor and its lymphan-giogenic eﬀects are mediated by VEGFR-3 [30,31]. However,
the increase in blood vascular permeability induced by
VEGF-C is mediated by VEGFR-2 [31]. Disruption of the
VEGF-C gene in mice demonstrates that the growth factor is
indispensable in embryonic lymphangiogenesis [32]. VEGF-C
is also involved in tumor and inﬂammation associated lym-
phangiogenesis. Examination of VEGF-C function in a num-
ber of assays has also shown an angiogenic activity,
presumably via activation of VEGFR-2. VEGF-C gene trans-
fer produced moderate angiogenesis in rabbit skeletal muscle
[3] and perivascular tissue [4].6. VEGF-D
VEGF-D is a secreted glycoprotein and is structurally 48%
identical to VEGF-C. VEGF-D is expressed in many adult tis-
sues including the vascular endothelium, heart, skeletal muscle,
lung, and bowel. The human VEGF-D gene is 2.0 kb in size
and is located on chromosome Xp22.31. The human VEGF-
D is proteolytically processed in its N-terminal and C-terminal
ends; the mature form binds to and activates VEGFR-2 and
VEGFR-3 [32]. However the mouse VEGF-D binds only to
VEGFR-3. VEGF-D has been shown to be responsible for
proliferation of ECs, and it shows angiogenic properties
in vitro and in vivo. Similar to VEGF-C, it also shows lymph-
angiogenic potential. The lack of a profound lymphatic vessel
defect in VEGF-D deﬁcient mice may reﬂect a subtle, redun-
dant, or nonexistent role of this growth factor during embry-
onic development [33]. Nonetheless, VEGF-D may induce
lymphatic vessel growth in adult life in response to pathologi-
cal conditions.
VEGF-D has been proposed to have a role in tumor angio-
genesis and lymphangiogenesis [34,35]. VEGF-D is able to in-
duce strong angiogenesis in addition to lymphangiogenesis in
the rabbit hindlimb muscles [7]. Adenovirus mediated gene
transfer of VEGF-D andmature VEGF-D in the periadventitial
space produces signiﬁcant activation of angiogenesis (Fig. 1)
and vascular smooth muscle cell (SMC) proliferation [4,12].7. VEGF-E
VEGF-E was discovered in the genome of the parapoxvirus
(Orf virus) that infects sheep, goats, and occasionally humans
[36]. Infection by this virus causes proliferative skin lesions in
which extensive capillary proliferation and dilation are prom-
inent histological features. Several strains of the virus encode
diﬀerent VEGF-E variants, which bind speciﬁcally to
VEGFR-2 and Nrp-1 and are able to stimulate EC mitogenesis
and vascular permeability. Gene expression of VEGF-E in-
duces a strong angiogenic response. Edematous lesions and
hemorrhagic spots on the ear which were reported as side ef-
fects in VEGF-A transgenic mice were not detectable in
VEGF-E transgenic mice [37,38].8. VEGF-F
Recently a seventh member of the VEGF family, VEGF-F,
was identiﬁed from snake (viper) venom. VEGF-F consists of
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and VR-1 (109 residues) that have a 50% primary structure
identity with VEGF-A165 and bind selectively to VEGFR-2
[39]. VEGF-F contains a short C-terminal heparin-binding
region and the C-terminal peptide of VEGF-F exhibits a spe-
ciﬁc blockage of VEGF-A165 activity both in vitro and
in vivo [40].9. VEGF receptors (VEGFR)
9.1. VEGFR-1
VEGFR-1 is expressed in ECs as well as pericytes, placental
trophoblasts, osteoblasts, monocytes/macrophages, renal mes-
angial cells and also in some hematopoietic stem cells [41].
VEGFR-1 binds VEGF-A, VEGF-B and PlGF with high
aﬃnity (Fig. 2). VEGFR-1 knockout mice die at early stages
of embryogenesis due to disorganization of blood vessels and
overgrowth of EC. VEGFR-1 transmits only weak mitogenic
signals in ECs, but it is known to form a heterodimer with
VEGFR-2, that has strong signaling properties [42].
VEGFR-1 activation at least by PlGF can also promote angi-
ogenesis, presumably through intracellular crosstalk with
VEGFR-2 [22]. VEGFR-1 is associated with monocyte chemo-
taxis and in the recruitment and survival of bone marrow de-
rived progenitor cells. VEGFR-1 expression is upregulated
during angiogenesis and also by hypoxia, unlike that ofVEGFR-1 VEG
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VEGFR-1, is able to inhibit VEGF action in humans and mice
and has been linked to preeclampsia [43].
9.2. VEGFR-2
VEGFR-2 (kinase-insert domain receptor,KDR/fetal liver ki-
nase,Flk-1) bindsVEGF-A,VEGF-CandVEGF-D.VEGFR-2
is the primary receptor transmitting VEGF signals in ECs
[38,41]. The VEGFR-2 signaling pathway is crucial in bringing
about the eﬀects of VEGFs including vasodilatation, endothelial
cell migration and proliferation (Fig. 2). Besides endothelial
cells, VEGFR-2 is also expressed by circulating endothelial pro-
genitor cells, pancreatic duct cells, retinal progenitor cells and
megakaryocytes [1]. VEGFR-2 may be associated with inte-
grin-dependent migration of ECs, as it forms a complex with
integrin aVb3 upon binding VEGF-A [44].
9.3. VEGFR-3
VEGFR-3 (fms-like tyrosine kinase 4, Flt4) binds VEGF-C
and VEGF-D. VEGFR-3 is present on all endothelia during
development but in the adult it becomes restricted to lymphatic
ECs and certain fenestrated blood vascular ECs [45]. Knock-
out and developmental studies suggest that VEGFR-3 signal-
ing is essential for development of blood vessels during
embryonic stage but becomes redundant in mature vessels.
However, VEGFR-3 is upregulated on ECs of vascular tu-FR-2 VEGFR-3
-F VEGF-C, VEGF-D
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e biological role of VEGFR-1 is currently unclear but it can act as a
R-1 is associated with monocyte chemotaxis. VEGFR-1 activation at
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C, phospholipase C; PI3K, phosphoinositide 3-kinase; PKC, protein
, diacylglycerol; eNOS, endothelial constitutive nitric oxide synthase;
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lymphangiogenesis (Fig. 2) Transgenic mice overexpressing a
soluble VEGFR-3-Ig fusion protein in the skin lack dermal
lymphatic vessels [46].9.4. Neuropilins
The neuropilins, Nrp-1 and Nrp-2, have roles in immunol-
ogy and neuronal development but they are also involved in
angiogenesis [2]. Neuropilins bind class 3 semaphorins, which
are secreted molecules that mediate repulsive signals during
neuronal axon guidance. Nrp-1 also binds VEGF-A165,
VEGF-B and PlGF while Nrp-2 binds VEGF-A165, VEGF-
C and PlGF [2]. Nrp-1 acts as a co-receptor enhancing
VEGF-VEGFR-2 interactions, forming complexes with
VEGFR-1. Overexpression of Nrp-1 in chimeric mice leads
to excessive formation of capillaries and blood vessels and
hemorrhages in addition to cardiac malformations [47]. It is
thought that Nrp-1 is required for cardiovascular development
because it regulates VEGF-A165 levels. In chick embryos,
endothelial Nrp-1 expression is mostly conﬁned to arteries,
whereas Nrp-2 primarily marks veins [48]. Nrp-2 is expressed
also on lymphatic ECs, and mutated Nrp-2 induces abnormal-
ities in the formation of small lymphatic vessels and lymphatic
capillaries in mice [49].10. VEGFs in cardiovascular pathology
10.1. Therapeutic angiogenesis for coronary artery disease and
peripheral artery disease (see Table 1)
Atherosclerotic narrowing of blood vessels causes a deceased
tissue perfusion and ischemia. Narrowing or occlusion of cor-
onary arteries and large peripheral arteries due to atheroscle-
rotic lesions could result in coronary artery disease (CAD)
and peripheral artery disease (PAD) [50,51]. Formation of col-
lateral vessels can improve perfusion in the ischemic tissues.
VEGFs have been used to promote development of collateral
blood vessels in clinical trials and animal models [3,51].
Improvement in exercise tolerance was reported after adenovi-
rus mediated VEGF-A121 gene transfer to ischemic myocar-
dium [51]. Animal experiments using intramuscular or
intramyocardial injections of adenovirus encoding VEGF-A
and VEGF-D, have shown high angiogenic eﬃcacy [3,5].
VEGF-A and VEGF-D enlarge the preexisting capillaries in
skeletal muscle and also enhance collateral growth. PlGF also
induces angiogenesis and arteriogenesis in animal models of
myocardial infarction and lower limb ischemia [23]. VEGF
overexpression increases vascular permeability and may cause
substantial tissue edema, pericardial eﬀusion in the heart and
angioma formation. Use of combination therapy using diﬀer-
ent growth factors like VEGF and angiopoietin might reduce
the side eﬀects [52].10.2. Intimal hyperplasia
Neointima formation occurs following an acute injury to the
blood vessels as seen after angioplasty, stent placement and in
vein graft stenosis. Multiple factors tend to inﬂuence the neo-
intima formation but vascular smooth muscle cell proliferation
is perhaps the most important factor responsible for the devel-
opment of restenosis [12]. VEGF-A, VEGF-D and PlGF can
inﬂuence smooth muscle cell migration.The role of VEGFs in intimal hyperplasia has remained con-
troversial. VEGF expression was detected in vascular SMC
after balloon injury which suggests that VEGFs may play a
role in the development of restenotic lesions [53]. Increased
neovascularization has also been observed at sites of intimal
hyperplasia. A correlation between adventitial angiogenesis
following VEGF gene transfer and intimal hyperplasia was
seen in a collar model of neointima formation [12]. However,
in a balloon denudation model of neointima formation, trans-
fer of VEGF gene to vessel wall has been shown to decrease
neointima formation [50,51]. VEGF stimulates endothelial
regeneration in injured blood vessels. It has been hypothesized
that the rapid regeneration of ECs results in secretion of sub-
stances like nitric oxide, C-type natriuretic peptide and prosta-
cyclin-I2, which have anti-proliferative eﬀects on smooth
muscle cells [51].
10.3. Atherosclerosis
Plaque angiogenesis may be associated with increased ath-
erogenesis and unstable vulnerable plaques. These vulnerable
plaques are more likely to rupture and cause sudden intra-arte-
rial occlusion. An abrupt, coronary artery occlusion following
a plaque rupture could result in fatal acute coronary syn-
drome. VEGFs are potent angiogenic factors that can aﬀect
plaque neovascularization and thereby inﬂuence atheroscle-
rotic process. Use of VEGFs for therapeutic angiogenesis in
CAD and PAD has been questioned because of the concerns
that the VEGFs might enhance the atherosclerotic lesion for-
mation. VEGF along with other growth factors and cytokines
can initiate and/or accelerate atherosclerosis by inﬂuencing
monocyte activation, adhesion, migration and enhancing vas-
cular permeability [54]. VEGF-A and VEGF-D, are expressed
in medial smooth muscle cells and in macrophages of human
atherosclerotic lesions. A role of PlGF in macrophage inﬁltra-
tion and development of early atherosclerotic lesions has also
been suggested [25]. The debate over the role of VEGFs in ath-
erosclerosis continues with a recent study in an animal model
showing that the increased systemic levels of VEGF-A,
VEGF-B, VEGF-C, and VEGF-D have no eﬀect on athero-
sclerotic lesions [55].11. Tumor angiogenesis and lymphangiogenesis
Malignant neoplasms are characterized by uncontrolled cel-
lular proliferation. Adequate blood supply and nutrients are
required to sustain their growth. Tumor growth and metastasis
are angiogenesis-dependent events. Role of VEGF in tumor
angiogenesis, especially in lung, gastrointestinal, ovarian and
breast cancers has been investigated and tumor angiogenesis
has become a potential target for cancer therapy [56]. Bev-
acizumab (Avastin), a neutralizing monoclonal antibody to
VEGF, was the ﬁrst antiangiogenic agent that was approved
for the treatment of metastatic colorectal cancer. Since then
it has also been experimentally used for treatment of other can-
cers (see Table 1).
VEGF-B and PlGF act through VEGFR-1 and their role in
tumor angiogenesis has also been investigated. Increased PlGF
expression has been associated with pathological angiogenesis
[18]. PlGF expression is signiﬁcantly increased in non-small
cell lung carcinoma tissues and in certain brain tumors.
VEGF-B presumably has a role in early tumor development
Table 1
Potential clinical applications of VEGFs and VEGF inhibitors
Disease Therapeutic agent Potential clinical use Comments
CAD PAD VEGF-A, VEGF-D, PlGF Therapeutic angiogenesis Neo-angiogenesis/arteriogenesis
to restore blood supply to
ischemic areas
Wound healing and bone
healing
VEGF-A, VEGF-C, VEGF-D,
PlGF
Therapeutic angiogenesis,
lymphangiogenesis
Angiogenesis to hasten wound/
bone healing. Restore lymphatic
supply across incisional wounds.
Lymphedema VEGF-C, VEGF-D Therapeutic lymphangiogenesis Improved lymphatic drainage
Restenosis – post
angioplasty, stent
VEGF-A, VEGF-C, VEGF-D Suppress intimal hyperplasia Rapid endothelial regeneration
Vein graft VEGF-D (Trinam) Improved vein graft survival Increased adventitial
angiogenesis
Tumor angiogenesis,
lymphangiogenesis
VEGF inhibitors e.g. monoclonal
antibody
VEGF-A (Avastin), soluble
VEGF receptors (VEGF Trap)
Inhibit tumor angiogenesis,
lymphangiogenesis
Can be used in conjunction with
other therapies. Reduce tumor
growth and metastasis
Rheumatoid arthritis VEGF inhibitors Reduce angiogenesis in pannus Can be used in conjunction with
other therapies to reduce
inﬂammation and angiogenesis
Psoriasis VEGF-A inhibitors Decrease angiogenesis and
inﬂammation
Can be used in conjunction with
other therapies to reduce
inﬂammation and angiogenesis
Ocular disorders – DR,
AMD, ROP
VEGF-A inhibitors, VEGF trap,
Macugen
Suppress angiogenesis These ocular diseases are
characterized by abnormal
angiogenesis
PAD, peripheral arterial disease; CAD, coronary artery disease; DR, diabetic retinopathy; AMD, age related macular degeneration; ROP, reti-
nopathy of prematurity.
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conclusive data to indicate a signiﬁcant role of VEGF-B in tu-
mor progression [27].
Lymphatic vasculature provides another route for tumor
metastasis. Certain tumors like carcinomas of breast, lung
and gastrointestinal tract have a propensity to metastasize
through lymphatic vessels. The production of lymphangio-
genic growth factors VEGF-C, VEGF-D and their receptor
VEGFR-3 stimulate lymphatic growth in the region of the tu-
mor, enabling cancer cells to gain access to the lymphatic vas-
culature [57]. VEGF-C and VEGF-D have been associated
with tumor lymphangiogenesis and metastatic spread of tumor
cells and a role of VEGF-A in peritumoral lymphangiogenesis
and lymphatic metastasis has also been proposed.12. Lymphedema
Impaired drainage results in the retention of lymphatic ﬂuid
in subcutaneous tissues. Lymphedemas can be classiﬁed as
hereditary (primary) or acquired (secondary). VEGFR-3 is
important for normal lymphatic vascular functions. In some
patients with congenital hereditary lymphedema (Milroy dis-
ease), missense mutations in the TK domain of VEGFR-3
interferes with the signaling and results in lymphedema [58].
VEGF-C gene therapy in lymphedema animal model has
shown promising results.13. Role of VEGFs in wound healing
Revascularization of damaged tissue is an important compo-
nent of wound healing. Inadequate or unregulated vessel
growth could result in a delayed healing. VEGF is widely ex-pressed during diﬀerent phases of wound healing and its role
is critical in this process. Several preclinical studies have been
done to study VEGF as a potential therapeutic factor in
wound healing [59]. The overexpression of VEGF using gene
therapy techniques resulted in an increased vascular density
in the wound and a more rapid closure of the wound, but there
is a signiﬁcantly greater deposition of granulation tissue.
Adenovirus mediated VEGF-A165 gene transfer and adeno-
associated virus mediated VEGF gene transfer has been used
to promote ﬂap survival and wound healing in animal models
[59]. Adenoviral VEGF-C gene transfer at the edges of epigas-
tric skin ﬂaps in mice results in the formation of anastomoses
between the lymphatic vessels of the skin ﬂap and the sur-
rounding lymphatic vasculature [60]. In skin, PlGF expression
is upregulated during wound healing and PlGF-deﬁcient mice
show delayed wound closure, indicating that this factor pro-
motes angiogenesis during skin repair [61].14. VEGF in rheumatoid arthritis (RA)
Angiogenesis constitutes an early event of synovial hyperpla-
sia which presumably promotes the destruction of cartilage
and bone in later stages of RA. The role of angiogenesis is
intricate and varied in RA. Angiogenesis helps in supplying
nutrients for hyperplastic synovium but also promotes persis-
tence of synovial inﬂammation through the inﬂux of inﬂamma-
tory cells and by producing inﬂammatory mediators [62]. The
neovascular network in RA is dysfunctional and the joint af-
fected by rheumatoid arthritis is hypoxic. VEGF is upregu-
lated by proinﬂammatory cytokines and by hypoxia in RA
[63]. Anti-angiogenic strategies including bevacizumab (a neu-
tralizing monoclonal antibody to VEGF) may have a potential
therapeutic role in RA [64].
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15.1. Diabetic retinopathy
Diabetic retinopathy (DR) becomes clinically apparent sev-
eral years after the onset of diabetes mellitus (DM). Non-pro-
liferative diabetic retinopathy (NPDR) is characterized by
increased vascular permeability, leading to edema, and lipo-
protein accumulation (hard exudates) in the outer plexiform
layer and small haemorrhages and microaneurysms in retina
[65]. In later stages there is periretinal neovascularization
which typiﬁes the proliferative diabetic retinopathy (PDR). In-
creased VEGF-A expression has been described in NPDR in
humans and elevated levels of VEGF-A have been found in
the aqueous humor and vitreous of patients with PDR. VEGF
receptors are also upregulated in DR [66]. Increased VEGF-A
levels presumably result in vascular leakage and periretinal
neovascularization in DR.15.2. Age-related macular degeneration
Age-related macular degeneration (AMD) is the major cause
of central vision loss in elderly. There are two forms of AMD,
neovascular and non-neovascular. The non-neovascular form
of AMD is more common. Visual loss in AMD occurs from
photoreceptor damage due to development of choroidal neo-
vascularization (CNV) and related manifestations such as sub-
retinal hemorrhage, detachment of the retinal pigmentary
epithelium (RPE), and ﬁbrovascular disciform scarring [67].
Vitreous VEGF-A levels were found to be signiﬁcantly higher
in patients with AMD and CNV [66]. Although the exact
mechanisms for development of CNV are poorly understood,
tissue hypoxia and VEGF overexpression presumably play a
key role in the development of CMV [66,67].15.3. Retinopathy of prematurity (ROP)
ROP is characterized by the proliferation of the retinal
blood vessels in premature babies who receive prolonged
mechanical ventilation and are therefore exposed to high con-
centrations of oxygen. Role of VEGF has been clearly estab-
lished in the pathogenesis of ROP [66,68]. Hyperoxia causes
obliteration of developing retinal vessels. Once the infant re-
turns to normoxic environment retina become hypoxic, result-
ing in VEGF upregulation and vascular proliferation [66,68].
VEGF is expressed by the astrocytes and the Mu¨ller cells
which participate in the development of the superﬁcial and
deep vascular layers, respectively. Insulin like growth factor
(IGF)-1 also plays an important role in development of
ROP. It has been suggested that VEGF may not be able to
stimulate vascular growth in absence of IGF-1 [66].16. Psoriasis
Psoriasis is a chronic inﬂammatory skin disease character-
ized by epidermal hyperplasia, impaired epidermal diﬀerentia-
tion, and accumulation of distinct leukocyte subpopulations.
VEGF is strongly upregulated in psoriatic skin lesions [69].
Single nucleotide polymorphisms of the VEGF gene occur
more frequently in patients with early onset psoriasis and these
haplotypes may contribute to the elevated VEGF levels ob-
served in these patients [70]. Thus VEGF plays an important
role in the pathogenesis of psoriasis and that therapeuticblockade of the VEGF/VEGF-receptor system might represent
a novel, pharmacogenomic approach for the future treatment
of psoriasis.17. Conclusions
Recent advancements in vascular research have enhanced
our understanding of VEGF/VEGF-receptor biology. These
molecules are crucial regulators of vasculogenesis, angiogene-
sis and lymphangiogenesis. Several, VEGF/VEGF-receptor
inhibition strategies have emerged for treating the diseases
associated with pathological angiogenesis. Similarly ‘therapeu-
tic angiogenesis’ is an emerging treatment modality for ische-
mic disorders. Future advances in our understanding of
biology of VEGFs are likely to identifying newer functions
and potential therapeutic uses for these molecules.Acknowledgements: This study was supported by grants from Finnish
Academy, Finnish Foundation for Cardiovascular Research and Euro-
pean Union (QLK3-CT-2002-01955) and (LSHG-CT-2004-503573).References
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